Both ImmuCell Corporation (NASDAQ:ICCC) and BioSpecifics Technologies Corp. (NASDAQ:BSTC) compete on a level playing field in the Biotechnology industry. We will evaluate their performance with regards to institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation.
Earnings and Valuation
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|BioSpecifics Technologies Corp.||64||12.90||N/A||2.73||24.24|
We can see in table 1 the earnings per share, gross revenue and valuation of ImmuCell Corporation and BioSpecifics Technologies Corp.
Table 2 demonstrates the net margins, return on assets and return on equity of ImmuCell Corporation and BioSpecifics Technologies Corp.
|Net Margins||Return on Equity||Return on Assets|
|BioSpecifics Technologies Corp.||0.00%||0%||0%|
Risk and Volatility
A 1.18 beta indicates that ImmuCell Corporation is 18.00% more volatile compared to S&P 500. BioSpecifics Technologies Corp.’s 1.24 beta is the reason why it is 24.00% more volatile than S&P 500.
2.5 and 1.6 are the respective Current Ratio and a Quick Ratio of ImmuCell Corporation. Its rival BioSpecifics Technologies Corp.’s Current and Quick Ratios are 27.1 and 27.1 respectively. BioSpecifics Technologies Corp. has a better chance of clearing its pay short and long-term debts than ImmuCell Corporation.
The following table given below contains the ratings and recommendations for ImmuCell Corporation and BioSpecifics Technologies Corp.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|BioSpecifics Technologies Corp.||0||0||1||3.00|
BioSpecifics Technologies Corp. on the other hand boasts of a $85 consensus target price and a 41.20% potential upside.
Insider and Institutional Ownership
Institutional investors owned 19.1% of ImmuCell Corporation shares and 63.5% of BioSpecifics Technologies Corp. shares. About 4.9% of ImmuCell Corporation’s share are owned by insiders. Insiders Comparatively, owned 0.1% of BioSpecifics Technologies Corp. shares.
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|BioSpecifics Technologies Corp.||-3.75%||-1.43%||-2.63%||14.13%||59.21%||9.16%|
For the past year ImmuCell Corporation has -12.58% weaker performance while BioSpecifics Technologies Corp. has 9.16% stronger performance.
BioSpecifics Technologies Corp. beats ImmuCell Corporation on 9 of the 9 factors.
ImmuCell Corporation develops, acquires, manufactures, and sells products that enhance animal health and productivity of cows for the dairy and beef industries in the United States and internationally. The company offers First Defense, an orally delivered scours preventive product for calves; Wipe Out Dairy Wipes, which consist of towelettes that are pre-moistened with a Nisin-based formulation to prepare the teat area of a cow in advance of milking; and California Mastitis Test that could be used for bulk tank and individual cow sample monitoring, as well as to determine which quarter of the udder is mastitic. It is also involved in the development of Mast Out, a Nisin-based treatment of subclinical mastitis in lactating dairy cows; and treatments that prevent E. coli K99 and bovine coronavirus, as well as calf scours caused by enteric pathogens. In addition, the company sells various product applications of its First Defense Technology, including a whey protein concentrate for the nutritional and feed supplement markets. ImmuCell Corporation sells its products to distributors and bovine veterinarians, as well as directly to producers. The company was founded in 1982 and is based in Portland, Maine.
BioSpecifics Technologies Corp., a biopharmaceutical company, engages in the development of an injectable collagenase clostridium histolyticum for multiple indications in the United States. The company offers injectable collagenase for the treatment of DupuytrenÂ’s contracture and PeyronieÂ’s disease under the XIAFLEX brand in Canada and Australia, as well as under XIAPEX brand name in Europe. It also provides injectable collagenase to treat frozen shoulder, cellulite, canine lipoma, lateral hip fat, and plantar fibromatosis, as well as for the treatment of human lipoma and uterine fibroids. The company is also involved in the development of other clinical indications for which collagenase injection has been tested, such as keloids, hypertrophic scars, scarred tendons, glaucoma, herniated intervertebral discs, and as an adjunct to vitrectomy. It has a development and license agreement with Endo Global Ventures. BioSpecifics Technologies Corp. was founded in 1957 and is headquartered in Lynbrook, New York.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.